Earnings summaries and quarterly performance for Minerva Neurosciences.
Research analysts who have asked questions during Minerva Neurosciences earnings calls.
Andrew Tsai
Jefferies
5 questions for NERV
Also covers: ARQT, ATAI, ATHA +13 more
DT
Douglas Tsao
H.C. Wainwright & Co.
5 questions for NERV
Also covers: ALKS, APLS, ARGX +19 more
JB
Jason Butler
JMP Citizens
1 question for NERV
Also covers: ACAD, AQST, ATHA +9 more
MM
Myles Minter
William Blair & Company
1 question for NERV
Also covers: ALEC, ARCT, ARGX +11 more
Thomas Shrader
BTIG
1 question for NERV
Also covers: ABOS, ALEC, ARCT +8 more
Recent press releases and 8-K filings for NERV.
Minerva Details Confirmatory Phase III Trial for Roluperidone in Schizophrenia Negative Symptoms
NERV
New Projects/Investments
Guidance Update
- Minerva is developing roluperidone as a potential first treatment for negative symptoms in schizophrenia, addressing a significant unmet medical need.
- The company has aligned with the FDA on the design of a confirmatory Phase III trial, which will evaluate roluperidone (64 mg) as monotherapy against placebo over 12 weeks for efficacy, with a key secondary endpoint on functioning (PSP). The trial is designed to enroll 380 patients and is 90% powered for the 12-week efficacy portion.
- The first patient for the Phase III trial is expected in Q2 2026, with top-line results for the primary efficacy endpoint anticipated in the second half of 2027, and relapse data in the second half of 2028.
- Roluperidone has demonstrated an effect on avolition, a key driver of negative symptoms, and previous studies showed low relapse rates of positive symptoms, which has reassured the FDA.
1 hour ago
Minerva Neurosciences, Inc. Announces 2025 Annual Meeting Results
NERV
Proxy Vote Outcomes
Executive Compensation
Convertible Preferred Issuance
- Minerva Neurosciences, Inc. held its 2025 Annual Meeting of Stockholders on December 22, 2025.
- Stockholders approved an amendment to the Amended and Restated 2013 Equity Incentive Plan, increasing the aggregate number of shares authorized for issuance under the plan by 12,500,000 shares.
- The company's stockholders approved an increase in the total number of authorized shares of Common Stock from 125,000,000 shares to 250,000,000 shares.
- Approval was also granted for the issuance of Common Stock upon the conversion of the company's Series A Convertible Voting Preferred Stock.
Dec 22, 2025, 9:05 PM
Minerva Neurosciences Announces Up to $200 Million Financing
NERV
Convertible Preferred Issuance
Board Change
New Projects/Investments
- Minerva Neurosciences announced a financing of up to $200 million to advance roluperidone for the treatment of negative symptoms in patients with schizophrenia through a Phase 3 confirmatory trial, resubmission of its New Drug Application (NDA), and preparation for US commercial launch.
- The financing includes $80 million upfront in exchange for Series A Convertible Preferred Stock, with up to an additional $80 million subject to the full exercise of Tranche A warrants, and a further $40 million contingent upon the cash exercise of Tranche B warrants upon achievement of a milestone event.
- The company expects these proceeds to sufficiently fund its operations through the confirmatory Phase 3 trial for roluperidone and the resubmission of its NDA.
- The closing of the private placement is expected on or about October 23, 2025, and will result in the appointment of up to three additional directors with significant schizophrenia clinical trial experience to Minerva's board.
Oct 22, 2025, 12:25 AM
Fintool News
In-depth analysis and coverage of Minerva Neurosciences.
Quarterly earnings call transcripts for Minerva Neurosciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more